Albireo Pharma, Inc. ALBO
Set alert
44.15 0.00 0.00%
At close · Mar 2
44.00 Day range 44.90
52-week range unavailable
- Open
- 44.90
- Prev close
- 44.15
- Mkt cap
- 915.89M
- Vol
- 1.24M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 44.00
- High
- 44.90
- Forward P/E
- -6.81
- Beta
- 1.04
- Short ratio
- 1.38
- Inst. own
- 107.69%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 7, 2023
- 50-d avg
- 38.96
- 200-d avg
- 25.30
- 1y target
- 42.00
Analyst view
Consensus: hold
Hold
Price target (mean) 42.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy3
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 7
- 2 months ago 7
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.97 | -1.97 – -1.97 | -0.57 | -245.6% | 9.63M | -70.4% | 2 |
| Next quarter | -1.76 | -1.95 – -1.57 | -2.19 | +19.6% | 11.75M | +72.0% | 2 |
| Current year | -7.79 | -8.13 – -7.45 | -1.77 | -340.1% | 34.38M | -15.3% | 2 |
| Next year | -6.48 | -6.95 – -6.02 | -7.79 | +16.8% | 61.65M | +79.3% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 15, 2023 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Jan 11, 2023 | Guggenheim | Downgrade | Buy | Neutral |
| Jan 11, 2023 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Jan 11, 2023 | Jefferies | Downgrade | Buy | Hold |
| Jan 10, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jan 9, 2023 | Wedbush | Downgrade | Outperform | Neutral |
| Oct 13, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Oct 12, 2022 | Baird | Maintained | — | Outperform |
| Sep 8, 2022 | Guggenheim | Initiated | — | Buy |
| Aug 16, 2022 | Wedbush | Maintained | — | Outperform |
| Aug 16, 2022 | Baird | Maintained | — | Outperform |
| Aug 16, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| May 17, 2022 | Baird | Maintained | — | Outperform |
| Nov 5, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 16, 2021 | Wedbush | Maintained | — | Outperform |
| Jul 21, 2021 | Wedbush | Maintained | — | Outperform |
| Jul 21, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 1, 2021 | Piper Sandler | Maintained | — | Overweight |
| Sep 8, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 8, 2020 | Needham | Maintained | — | Buy |
| Aug 19, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Jul 31, 2020 | Piper Sandler | Initiated | — | Overweight |
| Jun 25, 2020 | Baird | Initiated | — | Outperform |
| Mar 3, 2020 | Wedbush | Maintained | — | Outperform |
| Feb 28, 2019 | H.C. Wainwright | Initiated | — | Buy |
| Apr 20, 2018 | Jefferies | Initiated | — | Buy |
| Nov 15, 2017 | Roth Capital | Initiated | — | Buy |
| Aug 16, 2017 | Cowen & Co. | Initiated | — | Outperform |
| Jul 18, 2017 | Needham | Initiated | — | Buy |
| Jun 30, 2017 | Wedbush | Initiated | — | Outperform |